Bloom Science Appoints Medicine Development Expert Dr. Stephen Wright to Clinical Advisory Board
SAN DIEGO, Calif., January 4, 2023 — Dr. Stephen Wright joins Bloom Science, Inc., a clinical-stage biotechnology company developing novel medicines for neurological diseases and conditions, as a senior scientific and medical advisor alongside clinical advisors Jacqueline French, MD and Eric Kossoff, MD. The clinical advisory board provides guidance on Bloom’s discovery, development, and commercialization of new generation medicines – live biotherapeutic products (LBPs) – to treat neurological diseases.
Dr. Wright brings to Bloom over 30 years of biotech and pharmaceutical expertise developing medicines, including: Epidiolex, a prescription medicine that is used to treat seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, or tuberous sclerosis complex in patients one year of age and older; and approval of the first second-generation 5 lipoxygenase inhibitor.
He served as chief medical officer and an executive member of the main board of directors of GW Pharmaceuticals from 2005 to 2018. He joined GW from Ispen, where he was senior vice president of clinical research and development and a member of the UK board of directors. Dr. Wright also served as venture head of neuroscience at Abbott Laboratories. He has numerous higher degrees and has authored over 100 publications. Dr. Wright is a visiting professor in the School of Chemistry, Food, and Pharmacy at The University of Reading.
“Bloom is thrilled to receive Dr. Stephen Wright’s innovative medical expertise as a member of our respected clinical advisory board as we advance our lead program to develop an orally-administered LBP to treat Dravet syndrome and other epileptic diseases,” said Christopher Reyes, PhD, CEO, founder, and director of Bloom Science.
Bloom clinical advisory board member Dr. French serves as chief scientific officer of the Epilepsy Foundation. She is also a professor of neurology in the Epilepsy Section at the New York University Langone Medical Center. Dr. French also serves as director of the Epilepsy Study Consortium, a nonprofit organization devoted to speeding new therapies through the development process and into the clinic.
Bloom medical advisor Dr. Kossoff is director of the Child Neurology Residency Program and a professor of neurology at Johns Hopkins Medicine. His expertise and research is in seizures and epilepsy, Ketogenic diet and Atkins diet for children and adults, infantile spasms, and Sturge-Weber syndrome.
ABOUT BLOOM SCIENCE
Bloom Science is a clinical-stage biotechnology company on a mission to bring transformative live biotherapeutic products (LBPs) to underserved patients with rare or complex neurological diseases who have not adequately responded to existing therapies. Bloom is taking a fundamentally different path to developing medicines by harnessing our expanding insight into how the gut microbiome modulates key processes in the immune system, nervous system and brain. Bloom has developed a platform to investigate how changes in the gut microbiome influence brain biochemistry and immune system activity that it can leverage to develop multi-functional therapeutics addressing multi-pathway driven neurological disorders. Learn more: https://bloomscience.com/